¼¼°èÀÇ »ç¸£Åº ½ÃÀå º¸°í¼­(2025³â)
Sartans Global Market Report 2025
»óǰÄÚµå : 1760707
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,222,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 8,993,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,765,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

»ç¸£Åº ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¸î ³â µ¿¾È ²ÙÁØÇÑ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀå Àü¸ÁÀº º¹ÇÕ ¿ä¹ý¿¡ ´ëÇÑ °ü½É Áõ°¡, Á¦¾à ¿¬±¸ °³¹ß¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡, ½ÅÈï ½ÃÀåÀÇ ¼ö¿ä Áõ°¡, ÀÇ·á ÀÎÇÁ¶óÀÇ È®´ë, »ýȰ ½À°üº´ÀÇ À¯Çà µî ¿©·¯ ¿äÀο¡ ±âÀÎÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ±â°£ µ¿¾È ¿¹»óµÇ´Â ÁÖ¿ä µ¿ÇâÀ¸·Î´Â ÀǾàǰ Àü´Þ ±â¼úÀÇ ¹ßÀü, API¸¦ À§ÇÑ Ã·´Ü Á¦Á¶ °øÁ¤ÀÇ °³¹ß, °íÁ¤ ¿ë·® º¹ÇÕ ÀǾàǰÀÇ °³¹ß, °³ÀÎ ¸ÂÃãÇü °íÇ÷¾Ð Ä¡·áÀÇ Çõ½Å, »õ·Î¿î »ç¸£Åº À¯µµÃ¼ÀÇ °³¹ß µîÀÌ ÀÖ½À´Ï´Ù.

°íÇ÷¾ÐÀÇ À¯º´·üÀÌ Áõ°¡Çϸ鼭 »ç¸£Åº ½ÃÀåÀÇ ¼ºÀåÀÌ ÃËÁøµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °íÇ÷¾ÐÀº Áö¼ÓÀûÀ¸·Î ³ôÀº Ç÷¾ÐÀÌ Áö¼ÓµÇ´Â ÁúȯÀ¸·Î, ½ÉÀ庴, ³úÁ¹Áß ¹× ±âŸ ½É°¢ÇÑ °Ç°­ ÇÕº´ÁõÀÇ À§ÇèÀ» ³ôÀÔ´Ï´Ù. °íÇ÷¾ÐÀÇ ¹ß»ý·üÀº ¼Ò±Ý°ú °¡°ø½ÄǰÀÌ ¸¹Àº ½Ä½À°ü°ú ¹ÐÁ¢ÇÏ°Ô ¿¬°üµÇ¾î ÀÖÀ¸¸ç, À̴ ü¾× Àú·ù¿Í ½ÉÀå¿¡ Ãß°¡ÀûÀÎ ºÎ´ãÀ» ÃÊ·¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. »ç¸£ÅºÀº Ç÷°üÀ» ¼öÃà½ÃŰ´Â È£¸£¸óÀÎ ¾ÈÁö¿ÀÅٽŠII¸¦ Â÷´ÜÇÏ¿© °íÇ÷¾ÐÀ» °ü¸®ÇÕ´Ï´Ù. Ç÷°üÀ» À̿ϽÃ۰í È®Àå½ÃÄÑ Ç÷¾ÐÀ» ³·Ãß°í ½ÉÀåÀÇ ºÎ´ãÀ» ÁÙÀÌ´Â °ÍÀÌ »ç¸£ÅºÀÇ ÁÖ¿ä ÀÛ¿ë ¸ÞÄ¿´ÏÁòÀÔ´Ï´Ù. ¿¹¸¦µé¾î, 2024³â 1¿ù, ¹Ì±¹ ½ÉÀå Çùȸ´Â 2022³â¿¡ °íÇ÷¾ÐÀ¸·Î ÀÎÇÑ »ç¸ÁÀÚ ¼ö°¡ 13¸¸ 1,454¸íÀ¸·Î 2021³â 12¸¸ 4,508¸í¿¡¼­ Áõ°¡ÇÑ °ÍÀ¸·Î º¸°íÇß½À´Ï´Ù.

»ç¸£Åº ½ÃÀåÀÇ ¼±µµ ±â¾÷µéÀº Ä¡·á È¿´É°ú ȯÀÚÀÇ ¼øÀÀµµ¸¦ °³¼±Çϱâ À§ÇØ Á¤Á¦ ÇüÅÂÀÇ »ç¸£Åº°ú °°Àº ÷´Ü Á¦Ç° °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °æ±¸¿ë ¾à¹°Àº »ç¸£Åº ÀǾàǰÀ» ÇÔÀ¯Çϰí ÀÖÀ¸¸ç, ¾ÈÁö¿ÀÅٽŠIIÀÇ È¿°ú¸¦ Â÷´ÜÇÏ¿© Ç÷°üÀ» À̿ϽÃ۰í Ç÷¾ÐÀ» ³·Ãä´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 7¿ù, Àεµ¿¡ º»»ç¸¦ µÐ Á¦¾à ȸ»çÀÎ Zydus Lifesciences´Â DiovanÀ̶ó´Â ºê·£µå¸íÀ¸·Î ÆÇ¸ÅµÇ´Â Valsartan Tablets USP (40mg, 80mg)¿¡ ´ëÇØ ¹Ì±¹ ½ÄǰÀǾ౹(FDA)ÀÇ ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù. ÀÌ Á¤Á¦´Â °íÇ÷¾Ð, ½ÉºÎÀü Ä¡·á ¹× ¼ºÀÎ ½ÉÀå ¸¶ºñ ÈÄ »ýÁ¸À² °³¼±À» À§ÇØ Ã³¹æµÇ¸ç, 1¼¼ ÀÌ»óÀÇ ¼Ò¾Æ ȯÀÚ¿¡°Ôµµ ÀûÇÕÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ªÀüÀï°ú °ü¼¼, Äڷγª 19 ¹× ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°, ±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

HBR
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Sartans, also known as angiotensin II receptor blockers (ARBs), are medications commonly prescribed to manage high blood pressure (hypertension) and heart failure. They work by blocking the action of angiotensin II, a hormone that constricts blood vessels, thereby promoting vessel relaxation, lowering blood pressure, and improving circulation. Sartans help reduce the risk of strokes, kidney damage, and heart attacks in individuals with specific cardiovascular conditions.

The main types of sartans include valsartan, telmisartan, losartan, irbesartan, azilsartan, and olmesartan. Valsartan, an angiotensin II receptor blocker (ARB), lowers blood pressure and reduces heart strain by relaxing blood vessels. It is distributed through various channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others. Valsartan is used for several applications, including hypertension, cardiovascular diseases, kidney diseases, and more, and is employed by various end-users such as hospitals, diagnostic laboratories, and others.

The sartans market research report is one of a series of new reports from The Business Research Company that provides sartans market statistics, including the sartans industry global market size, regional shares, competitors with the sartans market share, detailed sartans market segments, market trends, and opportunities, and any further data you may need to thrive in the sartans industry. This sartans market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The sartans market size has grown steadily in recent years. It will grow from $21.36 billion in 2024 to $22.39 billion in 2025 at a compound annual growth rate (CAGR) of 4.8%. The growth during the historic period can be attributed to factors such as the growing adoption of sedentary lifestyles, the increasing incidence of obesity, rising awareness about cardiovascular diseases, higher healthcare expenditure, and the rising demand for generic antihypertensive drugs.

The sartans market size is expected to see steady growth in the next few years. It will grow to $26.66 billion in 2029 at a compound annual growth rate (CAGR) of 4.5%. The forecasted growth can be attributed to several factors, including a heightened focus on combination therapies, increased investments in pharmaceutical R&D, rising demand in emerging markets, expanded healthcare infrastructure, and the growing prevalence of lifestyle-related disorders. Key trends expected during this period include advancements in drug delivery technologies, the development of advanced manufacturing processes for APIs, the creation of fixed-dose combination drugs, innovations in personalized hypertension treatments, and the development of novel sartan derivatives.

The rising prevalence of hypertension is expected to drive the growth of the sartans market. Hypertension, a condition characterized by persistently high blood pressure, increases the risk of heart disease, stroke, and other serious health complications. The growing incidence of hypertension is largely linked to diets high in salt and processed foods, which can lead to fluid retention and added strain on the heart. Sartans help manage hypertension by blocking angiotensin II, a hormone that causes blood vessels to constrict. By relaxing and widening the blood vessels, sartans lower blood pressure and reduce the heart's workload. For example, in January 2024, the American Heart Association reported that high blood pressure was responsible for 131,454 deaths in 2022, an increase from 124,508 deaths in 2021. As a result, the rising prevalence of hypertension is driving the growth of the sartans market.

Leading companies in the sartans market are focusing on developing advanced products, such as tablet-form sartans, to improve treatment efficacy and patient adherence. These oral medications contain sartan drugs, which block the effects of angiotensin II, promoting blood vessel relaxation and lowering blood pressure. For example, in July 2024, Zydus Lifesciences, an India-based pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for Valsartan Tablets USP (40 mg, 80 mg), marketed under the brand name Diovan. These tablets are prescribed to treat hypertension, heart failure, and to improve survival after a heart attack in adults, and are also suitable for pediatric patients aged one year and older.

In April 2025, Scienture Holdings, Inc., a U.S.-based manufacturer of sartans, partnered with Saptalis Pharmaceuticals to develop and distribute Arbli (losartan potassium oral suspension, 10 mg/mL). This collaboration includes warehousing and distribution agreements with strategic partners to ensure market readiness for the first FDA-approved ready-to-use oral liquid losartan, addressing unmet needs in the treatment of hypertension. Saptalis Pharmaceuticals is a U.S.-based pharmaceutical company.

Major players in the sartans market are Viatris Inc., Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Apotex Inc., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Cadila Pharmaceuticals Ltd., Lupin Ltd., Zydus Lifesciences Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Vasudha Pharma Chem Ltd., Unichem Laboratories Ltd., Global Pharma Tek, Manus Aktteva Biopharma LLP, Emcure Pharmaceuticals Ltd., Wellona Pharma, JPM Pharma & Chemicals Pvt. Ltd.

North America was the largest region in the sartans market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in sartans report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the sartans market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The sartans market consists of sales of candesartan, eprosartan, and fimasartan. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Sartans Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on sartans market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for sartans ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The sartans market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Sartans Market Characteristics

3. Sartans Market Trends And Strategies

4. Sartans Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Sartans Growth Analysis And Strategic Analysis Framework

6. Sartans Market Segmentation

7. Sartans Market Regional And Country Analysis

8. Asia-Pacific Sartans Market

9. China Sartans Market

10. India Sartans Market

11. Japan Sartans Market

12. Australia Sartans Market

13. Indonesia Sartans Market

14. South Korea Sartans Market

15. Western Europe Sartans Market

16. UK Sartans Market

17. Germany Sartans Market

18. France Sartans Market

19. Italy Sartans Market

20. Spain Sartans Market

21. Eastern Europe Sartans Market

22. Russia Sartans Market

23. North America Sartans Market

24. USA Sartans Market

25. Canada Sartans Market

26. South America Sartans Market

27. Brazil Sartans Market

28. Middle East Sartans Market

29. Africa Sartans Market

30. Sartans Market Competitive Landscape And Company Profiles

31. Sartans Market Other Major And Innovative Companies

32. Global Sartans Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Sartans Market

34. Recent Developments In The Sartans Market

35. Sartans Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â